Search
for
Sort by
Research 391–420 of 468
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
- Clinical Evaluation of COVID-19 Survivors at a Public Multidisciplinary Health Clinic
- Bicalutamide in Dermatology: A Narrative Review
- Depressive Disorder and Dermatological Autoimmune Diseases
- Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study
- Alopecia universalis after injection of messenger RNA COVID-19 vaccine. A case report
- Identifying long-term effects of SARS-CoV-2 and their association with social determinants of health in a cohort of over one million COVID-19 survivors
- Skin, mucosa and nail findings in hospitalized pediatric patients with Coronavirus disease-2019 (COVID-19)
- Prevalence and predictors of persistent post-COVID-19 symptoms
- The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
- Annual Convention in the Time of COVID
- Symptomatology of Long COVID Associated with Inherited and Acquired Thrombophilic Conditions: A Systematic Review
- Systematic review of exosome treatment in hair restoration: Preliminary evidence, safety, and future directions
- Perspective Chapter: Appraisal of Paclitaxel (Taxol) Pros and Cons in the Management of Cancer – Prospects in Drug Repurposing
- Correlations between soluble receptor for advanced glycation end products and heme oxogenase-1 in post-COVID-19 patients with telogen effluvium
- Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches
- Combination Therapy for Extensive Tumoral Calcinosis in Juvenile Dermatomyositis
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds
- The X Factor in Immunity: Sex Differences Shaped by the X Chromosome
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Real-world evidence in alopecia areata treatment: A narrative review
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Concomitant Alopecia Areata and Profound Bone Marrow Suppression: An Unusual Manifestation of Azathioprine Toxicity